Logo image of 1GRF.MI

GRIFOLS SA (1GRF.MI) Stock Price, Forecast & Analysis

Europe - Euronext Milan - BIT:1GRF - ES0171996087 - Common Stock

12.235 EUR
+1.75 (+16.69%)
Last: 1/15/2026, 7:00:00 PM

1GRF.MI Key Statistics, Chart & Performance

Key Statistics
Market Cap8.33B
Revenue(TTM)7.52B
Net Income(TTM)372.72M
Shares680.51M
Float287.00M
52 Week HighN/A
52 Week LowN/A
Yearly Dividend0
Dividend Yield0%
EPS(TTM)0.55
PE22.25
Fwd PE12.56
Earnings (Next)02-24
IPO2006-05-17
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
1GRF.MI short term performance overview.The bars show the price performance of 1GRF.MI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months

1GRF.MI long term performance overview.The bars show the price performance of 1GRF.MI in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of 1GRF.MI is 12.235 EUR.

GRIFOLS SA / 1GRF Daily stock chart

1GRF.MI Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to 1GRF.MI.


Chartmill TA Rating
Chartmill Setup Rating

1GRF.MI Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to 1GRF.MI. Both the profitability and the financial health of 1GRF.MI get a neutral evaluation. Nothing too spectacular is happening here.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

1GRF.MI Financial Highlights

Over the last trailing twelve months 1GRF.MI reported a non-GAAP Earnings per Share(EPS) of 0.55. The EPS increased by 160.05% compared to the year before.


Industry RankSector Rank
PM (TTM) 4.96%
ROA 1.88%
ROE 7.2%
Debt/Equity 1.76
Chartmill High Growth Momentum
EPS Q2Q%133.5%
Sales Q2Q%4.04%
EPS 1Y (TTM)160.05%
Revenue 1Y (TTM)7.31%

1GRF.MI Forecast & Estimates

20 analysts have analysed 1GRF.MI and the average price target is 17.08 EUR. This implies a price increase of 39.59% is expected in the next year compared to the current price of 12.235.

For the next year, analysts expect an EPS growth of 40.91% and a revenue growth 5.37% for 1GRF.MI


Analysts
Analysts75
Price Target17.08 (39.6%)
EPS Next Y40.91%
Revenue Next Year5.37%

1GRF.MI Ownership

Ownership
Inst Owners31.55%
Ins Owners6.36%
Short Float %N/A
Short RatioN/A

About 1GRF.MI

Company Profile

1GRF logo image Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. The company is headquartered in Sant Cugat Del Valles, Barcelona and currently employs 23,833 full-time employees. The company went IPO on 2006-05-17. The firm organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.

Company Info

GRIFOLS SA

Parque Empresarial Can Sant Joan, Avinguda de la Generalitat, 152-158

Sant Cugat del Valles BARCELONA ES

Employees: 23833

1GRF Company Website

1GRF Investor Relations

Phone: 34935710000

GRIFOLS SA / 1GRF.MI FAQ

Can you describe the business of GRIFOLS SA?

Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. The company is headquartered in Sant Cugat Del Valles, Barcelona and currently employs 23,833 full-time employees. The company went IPO on 2006-05-17. The firm organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.


What is the current price of 1GRF stock?

The current stock price of 1GRF.MI is 12.235 EUR. The price increased by 16.69% in the last trading session.


Does GRIFOLS SA pay dividends?

1GRF.MI does not pay a dividend.


What is the ChartMill rating of GRIFOLS SA stock?

1GRF.MI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


Is GRIFOLS SA (1GRF.MI) expected to grow?

The Revenue of GRIFOLS SA (1GRF.MI) is expected to grow by 5.37% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


What is the employee count for 1GRF stock?

GRIFOLS SA (1GRF.MI) currently has 23833 employees.